Ontology highlight
ABSTRACT:
SUBMITTER: O'Mara AE
PROVIDER: S-EPMC7190915 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
O'Mara Alana E AE Johnson James W JW Linderman Joyce D JD Brychta Robert J RJ McGehee Suzanne S Fletcher Laura A LA Fink Yael A YA Kapuria Devika D Cassimatis Thomas M TM Kelsey Nathan N Cero Cheryl C Sater Zahraa Abdul ZA Piccinini Francesca F Baskin Alison S AS Leitner Brooks P BP Cai Hongyi H Millo Corina M CM Dieckmann William W Walter Mary M Javitt Norman B NB Rotman Yaron Y Walter Peter J PJ Ader Marilyn M Bergman Richard N RN Herscovitch Peter P Chen Kong Y KY Cypess Aaron M AM
The Journal of clinical investigation 20200501 5
BACKGROUNDMirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adipose tissue (WAT) lipolysis, and insulin sensitivity.METHODSWe treated 14 healthy women of diverse ethnicities (27.5 ± 1.1 years of age, BMI of 25.4 ± 1.2 kg/m2) with 100 mg mirabegron (Myrbetriq extend ...[more]